Loading…
← CockpitCompetitor Analysis › KOD Kodiak Sciences, Inc.Open in the cockpit ↗

Kodiak Sciences, Inc.KODCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops long-acting biologic therapies for retinal diseases like wet age-related macular degeneration.

Momentum leader 100
Mkt cap
$6.40B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$83.1M
20-day average traded
P/B
500.31×
price to book
ROE
-1,360.9%
delivered
Implied ROE
6,084.6%
what the price asks
Next earnings
134 days
1 Apr 2027
Close · USD$97.81
1D+1.0%
1W-10.6%
1M+5.2%
3M+145.5%
6M+170.0%
YTD+249.8%
1Y+393.2%
ATR %7.1%
Beta0.27
52w lowhigh13.3% off high

What Kodiak Sciences does

Develops long-acting biologic therapies for retinal diseases like wet age-related macular degeneration.

Has no products on the market and no sales; operating costs are paid from money raised from investors, with cash use driven by late-stage trials. Future income depends on trial results and regulatory approval for tarcocimab and related antibody drugs.

Products and services

  • Tarcocimab (wet AMD, diabetic macular edema)

Customers

  • Ophthalmologists/retina specialists (post-approval

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Ophthalmology: retinal disease…

What could go right

  • Less-frequent dosing convenience if approved
  • Large retinal disease market

What could go wrong

  • History of trial failures and setbacks
  • Intensely competitive anti-VEGF market

Moat: none (IP / patents). Aims for less-frequent dosing than approved anti-VEGF drugs, but has faced repeated clinical setbacks.

Headquarters: Palo Alto, California, US · Founded: 2009 · Employees: 124

Named competitors

Kodiak Sciences at a glance

Size Kodiak Sciences (KOD) is a United States Health Care company (Biotechnology) with a market value of $6.40B, the 1011th largest of 3,085 United States companies the cockpit tracks. Shares closed at $97.81 on 18 Nov 2026.

Performance Over six months the shares gained 170.0%, against -1.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Valuation It trades at 500.31× book value against a peer median of 8.92× (most expensive of 21).

Price implies The share price implies a return on equity of about 6,084.6%; Kodiak Sciences delivers -1,360.9%, so the price asks more than the business earns today.

Short interest Short interest is 12.9% of the free float (30 Oct 2026).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

10020030021 May 202621 Aug 202618 Nov 2026KOD 261Peer median 100
Six months, rebased to 100: Kodiak Sciences against the median of its 20 peers (local-currency closes).

Kodiak Sciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$23.9M-$26.3M-$26.7M-$25.9M-$11.0M
EBITDA-$227M-$206M-$160M-$251M-$330M
Net income-$247M-$230M-$176M-$260M-$334M
Free cash flow-$173M-$137M-$118M-$196M-$254M
Capital expenditure$3.32M$506,000$400,000$41.4M$47.4M
Total debt$147M$159M$170M$182M$188M

Quarterly statements and history in the cockpit →

Kodiak Sciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%ARWRIMVTSRRKAXSMCGONCAIANTHEMTXG300122TWST300347SMMTCOGTDNTH1548196170ADPT002252EWTX000661KOD6-month return →1-month return →
Up and to the right = strong over both horizons. Kodiak Sciences is the large dot.

Fundamentals: return on equity against price-to-book

-1,000%-500%0%00×2000×4000×ARWRIMVTSRRKAXSMCGONSMMT196170ADPTKODReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Kodiak Sciences is the large dot.

Capital: ROE delivered against the ROE the price implies

0%2,000%4,000%6,000%0%2,000%4,000%6,000%ARWRIMVTSRRKAXSMKODROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. Kodiak Sciences is the large dot.

Kodiak Sciences competitors and peer comparison

Head to head with its named competitors (KOD vs REGN vs RO.SW vs OCUL)
CompanyMarket cap6M returnRevenue growthROEPrice / bookImplied ROE
Kodiak Sciences KOD$6.40B+170%n/a-1,361%500.31×6,084.6%
Regeneron Pharmaceuticals REGN$97.8B+46%+19%15%2.92×13.4%
Roche RO.SW$381B+21%-1%40%9.93×48.3%
Ocular Therapeutix OCUL$1.31B-26%-10%-93%2.96×27.2%
EyePoint EYPTn/a-98%n/an/an/an/a
4D Molecular Therapeutics FDMT$578M+23%+79,952%-57%1.74×32.0%
Novartis NOVN.SW$285B+11%-4%24%7.99×32.5%
REGENXBIO RGNX$480M+22%-5%-113%3.24×29.8%

How Kodiak Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kodiak Sciences against its 20 peers (data as of 18 Nov 2026)
MeasureKODPeer medianRank in peer set
1-month return+5.2%-6.2%8th highest of 21
6-month return+170.0%-1.4%highest of 21
Return on equity-1,360.9%-20.9%lowest of 21
Price / book500.31×8.92×most expensive of 21
ROE the price implies6,084.6%53.9%most demanding of 21
ROE delivered-1,360.9%-20.9%lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
Kodiak Sciences KODUnited States$6.40B+170%n/a-1,361%500.31×6,084.6%-1,360.9%
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-280%121.06×1,070.8%-280.5%
Immunovant IMVTUnited States$6.86B-7%n/a-87%10.44×74.1%-86.5%
Scholar Rock SRRKUnited States$5.86B-1%n/a-200%34.70×212.2%-200.0%
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-176%66.82×426.0%-175.6%
CG Oncology CGONUnited States$7.15B+24%+184%-28%7.21×30.5%-28.3%
Caris Life Sciences CAIUnited States$5.59B+24%+61%17%8.74×51.8%17.2%
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%20%15.70×125.3%20.4%
10x Genomics TXGUnited States$7.51B+138%-4%-8%8.95×112.5%-8.3%
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-64%2.32×24.5%-63.8%
Twist Bioscience TWSTUnited States$7.93B+117%+22%-19%8.89×121.3%-19.1%
Hangzhou Tigermed Consulting 300347.SZChina$4.88B-2%+16%-2%1.93×21.6%-2.0%
Summit Therapeutics SMMTUnited States$8.40B-41%n/a-220%14.87×56.0%-220.0%
Cogent Biosciences COGTUnited States$4.84B-16%n/a-100%10.72×44.4%-99.6%
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-23%3.81×39.0%-22.6%
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%-15%2.12×14.7%-15.3%
ALTEOGEN 196170.KSSouth Korea$8.80B-56%+61%46%21.49×91.7%46.3%
Adaptive Biotechnologies ADPTUnited States$4.61B+104%+18%-37%26.09×341.6%-37.1%
Shanghai RAAS Blood Products 002252.SZChina$4.57B-15%-22%3%0.94×3.8%3.3%
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/a92%2.77×14.2%92.1%
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-2%1.32×13.5%-1.9%

Questions

Who are Kodiak Sciences's main competitors?
Named competitors: Regeneron (Eylea) (REGN), Roche (Vabysmo) (RO.SW), Ocular Therapeutix (OCUL), EyePoint (EYPT), 4D Molecular Therapeutics (FDMT), Adverum Biotechnologies (private or unlisted). The cockpit's measured peer set (industry) also includes Arrowhead Pharmaceuticals (ARWR), Immunovant (IMVT), Scholar Rock (SRRK), Axsome Therapeutics (AXSM), CG Oncology (CGON), Caris Life Sciences (CAI).
Is Kodiak Sciences expensive compared with its peers?
On price / book it trades at 500.31× against a peer median of 8.92×, most expensive of 21 in its peer set. The share price implies a return on equity of about 6,084.6%; Kodiak Sciences delivers -1,360.9%, so the price asks more than the business earns today.
How has Kodiak Sciences stock performed?
Over six months to 18 Nov 2026 the shares returned +170.0% against -1.4% for the median peer; over one year +393.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.